新晋院士最新Science子刊：揭开多发性骨髓瘤起源细胞，开发CAR-T细胞疗法

Core Viewpoint - The research identifies the origin cells of multiple myeloma (MM) and develops a CAR-T cell therapy targeting FCRL5, demonstrating good safety and efficacy in treating relapsed or refractory multiple myeloma (RRMM) patients [3][9]. Group 1: Research Findings - The study utilized single-cell sequencing and genetic tracing analysis to investigate each developmental stage from hematopoietic stem cells to lymphoid lineage, identifying abnormal differentiation stages in multiple myeloma patients [5]. - The research team discovered that the long arm amplification of chromosome 1 (1q Amp) originates from a specific B cell subset, while the short arm deletion of chromosome 17 (17p Del) occurs at the plasma cell stage [6]. - 1q Amp is present in the CD24- FCRL5+ B cell subset, enhancing B cell proliferation and promoting plasma cell differentiation, which initiates the transformation of B cells into malignant plasma cells [6]. Group 2: Implications for Treatment - The findings establish genetic events associated with the initiation and malignant transformation of multiple myeloma in the B cell lineage, laying the groundwork for potential treatment strategies targeting multiple myeloma initiating cells (MIC) and their driver oncogenes in RRMM patients [11].